Palvella Therapeutics, Inc.
PVLA
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.04B
Close$
$5.10
96.6% downside
Current Fair Value
96.6% downsideOvervalued by 96.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.04 Billion |
|---|---|
| Enterprise Value | $1.85 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.71 |
| Beta | -0.17 |
| Outstanding Shares | 14,356,219 |
Return
| Return on Equity | -28.45% |
|---|---|
| Return on Assets | -24.34% |
| Return on Invested Capital | -17.54% |
Valuation & Multiples
| P/E Ratio | -29.41 |
|---|---|
| PEG | -22.46 |
| Price to Sales | - |
| Price to Book Ratio | 9.95 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -43.66 |
| Enterprise Value to Net Income | -30 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$-1.16
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 10, 2026
EPS Estimate
$-1.77
Average shareholder expectationRevenue Estimate
$16,667
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.9362▲ 66.81% |
|---|---|
| Total Calls | 247,800▼ 41.61% |
| Total Puts | 232,000▲ 103.87% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 120.89%▲ 19.96% |
|---|---|
| Total Invested | $2.16B▲ 31.81% |
| Investors Holding | 208▲ 18.00% |
ESG Score
No data
About Palvella Therapeutics, Inc.
14 employees
CEO: Mr. Wesley H. Kaupinen Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamy...